Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market for the ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

Eli Lilly & Co. raises Mounjaro prices in the United Kingdom to reduce costs in the U.S. Weight-loss drug prices increase by 170% in the U.K., but its National Health Service prices remained unchanged ...

The new approval allows the GLP-1 to be used to treat adults with the liver disease metabolic dysfunction-associated steatohepatitis (MASH) and liver scarring. Wegovy is the first GLP-1 to receive ...

The move follows a Trump administration push to reduce drug prices in America (or, at least, effectively level them across the world). In late July, the president sent letters to the CEOs of top U.S.

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Eli Lilly will increase the UK price of its Mounjaro treatment by 170% to match European markets. Despite Novo Nordisk's ...